AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9084795 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine (ZDV/3TC)
Number of subjects: 972
Study 9084795 — intervention group
Group type: COMPARATOR
Intervention: Control treatments (ZDV or ZDV/zalcitabine)
Number of subjects: 972
Study 8385971 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 0
Study 8385971 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 0
Study 2949027 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition
Number of subjects: 34
Study 2949027 — intervention group
Group type: COMPARATOR
Intervention: Intermittent enteral nutrition
Number of subjects: 34
Study 31249174 — intervention group
Group type: EXPERIMENTAL
Intervention: Air dry for 5 seconds
Number of subjects: 135
Study 31249174 — intervention group
Group type: EXPERIMENTAL
Intervention: Blot dry for 10 seconds
Number of subjects: 135
Study 31249174 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction dry for 10 seconds
Number of subjects: 135
Study 31249174 — intervention group
Group type: EXPERIMENTAL
Intervention: Air dry for 2 seconds
Number of subjects: 135
Study 31249174 — intervention group
Group type: EXPERIMENTAL
Intervention: Blot dry for 2 seconds
Number of subjects: 135
Study 31249174 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction dry for 2 seconds
Number of subjects: 135
Study 29973191 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity SC active referral (HAR Group)
Number of subjects: 68
Study 29973191 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity SC referral by text messaging (Text Group)
Number of subjects: 68
Study 29973191 — intervention group
Group type: COMPARATOR
Intervention: General very brief advice (Control Group)
Number of subjects: 68
Study 28082820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronase
Number of subjects: 0
Study 28082820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24685085 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH + GCS
Number of subjects: 247
Study 24685085 — intervention group
Group type: COMPARATOR
Intervention: GCS
Number of subjects: 247
Study 22440123 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 350
Study 22440123 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 350
Study 19071038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium perborate/37% carbamide peroxide paste
Number of subjects: 30
Study 19071038 — intervention group
Group type: COMPARATOR
Intervention: Sodium perborate/distilled water
Number of subjects: 30
Study 17443465 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 3 mg/kg per day
Number of subjects: 201
Study 17443465 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B 10 mg/kg per day
Number of subjects: 201
Study 15926874 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (vasopressin antagonist) in addition to standard therapy including diuretics
Number of subjects: 0
Study 15926874 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy including diuretics
Number of subjects: 0
Study 15926874 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 12355980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass vaccination against smallpox
Number of subjects: 0
Study 9690953 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-sotalol 300 mg
Number of subjects: 18
Study 9690953 — intervention group
Group type: EXPERIMENTAL
Intervention: (+/-)-sotalol 240 mg
Number of subjects: 18
Study 9690953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8589322 — intervention group
Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media diatrizoate (D)
Number of subjects: 0
Study 8589322 — intervention group
Group type: COMPARATOR
Intervention: Low-osmolar contrast media iopamidol (I)
Number of subjects: 0
Study 8589322 — intervention group
Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media diatrizoate (D) with captopril
Number of subjects: 0
Study 8589322 — intervention group
Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media diatrizoate (D) with nifedipine
Number of subjects: 0
Study 8589322 — intervention group
Group type: EXPERIMENTAL
Intervention: High-osmolar contrast media diatrizoate (D) unpretreated
Number of subjects: 0
Study 2807841 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline laparotomy (Group A)
Number of subjects: 32
Study 2807841 — intervention group
Group type: COMPARATOR
Intervention: Supraumbilical transverse laparotomy (Group B)
Number of subjects: 32
Study 1028632 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (non-amphetaminic anorexiant)
Number of subjects: 0
Study 1028632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with anorexiant
Number of subjects: 0
Study 1028632 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1028632 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 0
Study 30704697 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600mg twice daily
Number of subjects: 964
Study 30704697 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with long-acting inhaled bronchodilator(s) but no ICS
Number of subjects: 964
Study 30704697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 964
Study 27776269 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Number of subjects: 507
Study 27776269 — intervention group
Group type: COMPARATOR
Intervention: Counselor-delivered treatment (Arm 1)
Number of subjects: 507
Study 27776269 — intervention group
Group type: COMPARATOR
Intervention: Reduced TAU plus TES (Arm 2)
Number of subjects: 507
Study 27776269 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 507
Study 24846518 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with or without calcipotriol plus betamethasone dipropionate
Number of subjects: 730
Study 23393065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg orally) with 8 h of isocapnic hypoxia
Number of subjects: 8
Study 23393065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg orally) with 8 h of air breathing
Number of subjects: 8
Study 23393065 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 8 h of isocapnic hypoxia
Number of subjects: 8
Study 23393065 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 8 h of air breathing
Number of subjects: 8
Study 22040307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist Intervention Group (PIG)
Number of subjects: 154
Study 22040307 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 154
Study 17923015 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 group (HES group)
Number of subjects: 40
Study 17923015 — intervention group
Group type: COMPARATOR
Intervention: Gelatin group (GEL group)
Number of subjects: 40
Study 15826230 — intervention group
Group type: EXPERIMENTAL
Intervention: Break duration manipulation
Number of subjects: 0
Study 15826230 — intervention group
Group type: EXPERIMENTAL
Intervention: Break location manipulation
Number of subjects: 0
Study 15826230 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction time response at the end of the break
Number of subjects: 0
Study 12039485 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated cardiac troponin I (cTnI) after PCI
Number of subjects: 481
Study 12039485 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated cardiac troponin I (cTnI) after PCI (positive only after PCI)
Number of subjects: 481
Study 10469349 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures to avoid graft injury from immune and nonimmune mechanisms
Number of subjects: 0
Study 7898689 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ischemic lesions observed on CT
Number of subjects: 164
Study 7898689 — intervention group
Group type: COMPARATOR
Intervention: No ischemic lesions observed on CT
Number of subjects: 164
Study 2539403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg orally once per day
Number of subjects: 189
Study 2539403 — intervention group
Group type: COMPARATOR
Intervention: Captopril 12.5 mg orally three times per day
Number of subjects: 189
Study 2539403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 189
Study 2539403 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 189
Study 35075 — intervention group
Group type: EXPERIMENTAL
Intervention: Totamine synthetic amino acid solution, administered starting two days before surgery, providing 1200 calories and 12.4 g of nitrogen per day.
Number of subjects: 26
Study 35075 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving Totamine starting on the day of surgery, providing 1200 calories and 12.4 g of nitrogen per day.
Number of subjects: 26
Study 35075 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (preoperative and postoperative) receiving Totamine.
Number of subjects: 26
Study 31748198 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise advice and support (5-10 consultations with a physiotherapist) plus existing telephone service
Number of subjects: 175
Study 31748198 — intervention group
Group type: COMPARATOR
Intervention: Existing telephone service (≥1 nurse consultation for self-management advice)
Number of subjects: 175
Study 31748198 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise advice and support
Number of subjects: 175
Study 31522886 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT) with immediate knowledge of results (KR)
Number of subjects: 25
Study 31522886 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-meter walk test (10MWT) with immediate knowledge of results (KR)
Number of subjects: 25
Study 31522886 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT)
Number of subjects: 25
Study 31522886 — intervention group
Group type: COMPARATOR
Intervention: 10-meter walk test (10MWT)
Number of subjects: 25
Study 28177733 — intervention group
Group type: EXPERIMENTAL
Intervention: Block training (BL)
Number of subjects: 20
Study 25722382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecemotide
Number of subjects: 0
Study 25722382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25722382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecemotide (in concurrent chemoradiotherapy subgroup)
Number of subjects: 0
Study 25722382 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in concurrent chemoradiotherapy subgroup)
Number of subjects: 0
Study 23430455 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention for weight loss (weekly group sessions for 6 months, followed by 12 months of biweekly contacts)
Number of subjects: 218
Study 23430455 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention for weight loss
Number of subjects: 218
Study 22052225 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg orally once daily on days 5 to 11)
Number of subjects: 187
Study 22052225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 22052225 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 187
Study 22052225 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin and Placebo
Number of subjects: 187
Study 19481491 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 10
Study 16391577 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg/day folic acid (FA group)
Number of subjects: 32
Study 16391577 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.4 mg/day riboflavin (R group)
Number of subjects: 32
Study 16391577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both folic acid and riboflavin (FAR group)
Number of subjects: 32
Study 16391577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32
Study 15080016 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderberry syrup (15 ml, four times a day for 5 days)
Number of subjects: 60
Study 15080016 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 60
Study 12200354 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) and idarubicin regimen (AIDA regimen)
Number of subjects: 51
Study 9643523 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaposi's sarcoma-associated herpes virus identification in bone marrow stromal cells
Number of subjects: 500
Study 9522869 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-based oral rehydration solution (ORS)
Number of subjects: 20
Study 9522869 — intervention group
Group type: COMPARATOR
Intervention: Rice-based oral rehydration solution (ORS)
Number of subjects: 20
Study 2672871 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous fresh frozen plasma (FFP), 2 units (430 +/- 11 ml) given after the end of extracorporeal circulation (ECC)
Number of subjects: 40
Study 2672871 — intervention group
Group type: COMPARATOR
Intervention: Control group without FFP
Number of subjects: 40
Study 342625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent influenza A virus vaccines (200 or 400 CCA units of A/New Jersey/8/76 and A/Victoria/3/75)
Number of subjects: 234
Study 342625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 342625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent influenza A virus vaccines
Number of subjects: 234
Study 30967436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil + placebo
Number of subjects: 439
Study 30967436 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics + placebo
Number of subjects: 439
Study 30967436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil + probiotics
Number of subjects: 439
Study 30967436 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 439
Study 25562711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 59
Study 25562711 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 59
Study 23950585 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg intravenously once monthly (infusion every 4 weeks)
Number of subjects: 22
Study 21429078 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth ball usage
Number of subjects: 60
Study 21429078 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 19625629 — intervention group
Group type: EXPERIMENTAL
Intervention: Palosuran (5 to 2000 mg, oral doses)
Number of subjects: 72
Study 17445284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g high molecular weight (HMW) BBG
Number of subjects: 155
Study 17445284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g low molecular weight (LMW) BBG
Number of subjects: 155
Study 17445284 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g high molecular weight (HMW) BBG
Number of subjects: 155
Study 17445284 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g low molecular weight (LMW) BBG
Number of subjects: 155
Study 17445284 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 155
Study 15119878 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent silicone‐based resilient denture liner (SR)
Number of subjects: 28
Study 15119878 — intervention group
Group type: COMPARATOR
Intervention: Conventional heat‐activated acrylic resin (AR)
Number of subjects: 28
Study 11556937 — intervention group
Group type: EXPERIMENTAL
Intervention: General Medicine Clinic (GMC) with HIV-related training and evidence-based practice guidelines
Number of subjects: 214
Study 11556937 — intervention group
Group type: EXPERIMENTAL
Intervention: General Medicine Clinic (GMC)
Number of subjects: 214
Study 9623507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg)
Number of subjects: 20
Study 9623507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9623507 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-stimulated leukocyte supernatants
Number of subjects: 20
Study 8162723 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient pulmonary rehabilitation (OPR) for 6 weeks
Number of subjects: 20
Study 8162723 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting period of 6 weeks)
Number of subjects: 20
Study 3348665 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term ventilation of at least one ear
Number of subjects: 0
Study 3348665 — intervention group
Group type: EXPERIMENTAL
Intervention: Myringotomy for diagnosis
Number of subjects: 0
Study 30741655 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerounding in addition to standard rounds
Number of subjects: 80
Study 30741655 — intervention group
Group type: COMPARATOR
Intervention: Standard rounds
Number of subjects: 80
Study 30052097 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild processing (slow time constants, disabled frequency lowering)
Number of subjects: 40
Study 30052097 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong processing (fast time constants, frequency lowering enabled)
Number of subjects: 40
Study 26631833 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted decolonisation with chlorhexidine and mupirocin
Number of subjects: 122646
Study 26631833 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal decolonisation with chlorhexidine and mupirocin
Number of subjects: 122646
Study 26631833 — intervention group
Group type: COMPARATOR
Intervention: Screening and isolation
Number of subjects: 122646
Study 25277343 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual CPR
Number of subjects: 222
Study 25277343 — intervention group
Group type: COMPARATOR
Intervention: Mechanical CPR
Number of subjects: 222
Study 22360333 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐3075 cream (5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan) applied twice daily for 4 weeks
Number of subjects: 42
Study 22360333 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐3075 cream (5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan)
Number of subjects: 42
Study 22360333 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 42
Study 19217329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pain sensitivity in women
Number of subjects: 97
Study 19217329 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain sensitivity in women
Number of subjects: 97
Study 19217329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic pain sensitivity in women
Number of subjects: 97
Study 19217329 — intervention group
Group type: COMPARATOR
Intervention: Menstrual cycle influence on pain perception
Number of subjects: 97
Study 19217329 — intervention group
Group type: COMPARATOR
Intervention: Gender differences in pain sensitivity
Number of subjects: 97
Study 17426086 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological testosterone administration, 300 mug daily
Number of subjects: 51
Study 17426086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16330295 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg)
Number of subjects: 24
Study 16330295 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin (1.25 mg/250 mg BID for 6 days)
Number of subjects: 24
Study 16330295 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg) and Glyburide/Metformin coadministered
Number of subjects: 24
Study 12167274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) 100 mg bid SC injection
Number of subjects: 78
Study 12167274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) 50 mg bid SC injection
Number of subjects: 78
Study 12167274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) continuous subcutaneous infusion (CSI) 12.5, 25, 50 or 100 mg/day
Number of subjects: 78
Study 12167274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) subcutaneous injection (50 or 100 mg twice daily)
Number of subjects: 78
Study 10203570 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal A (600 g spinach)
Number of subjects: 20
Study 10203570 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal B (300 g spinach)
Number of subjects: 20
Study 10203570 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal C (0.4 mg folic acid in water)
Number of subjects: 20
Study 10203570 — intervention group
Group type: COMPARATOR
Intervention: Meal D (folate-free control meal)
Number of subjects: 20
Study 7607966 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (once daily 1.8‐2.0 Gy)
Number of subjects: 177
Study 7607966 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated split‐course irradiation (twice daily 1.6 Gy)
Number of subjects: 177
Study 7607966 — intervention group
Group type: COMPARATOR
Intervention: Definitive radiotherapy
Number of subjects: 177
Study 7607966 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery
Number of subjects: 177
Study 7607966 — intervention group
Group type: COMPARATOR
Intervention: Resection plus postoperative irradiation
Number of subjects: 177
Study 2393075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alfentanil (A1)
Number of subjects: 56
Study 2393075 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg alfentanil (A2)
Number of subjects: 56
Study 2393075 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg alfentanil (A3)
Number of subjects: 56
Study 2393075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 681295 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxapine (300 mg)
Number of subjects: 61
Study 681295 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline (150 mg)
Number of subjects: 61
Study 681295 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxapine
Number of subjects: 61
Study 681295 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 61
Study 681295 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxapine and amitriptyline
Number of subjects: 61
Study 31639034 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib monotherapy
Number of subjects: 109